Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Common Share (Tables)

Net Loss Per Common Share (Tables)

9 Months Ended

Sep. 30, 2013

Calculation of Basic and Diluted Net Loss Per Share

A calculation of basic and diluted net loss per share follows:


($ in thousands except share and per share amounts)	For the three months ended September 30,						For the nine months ended September 30,
($ in thousands except share and per share amounts)	2013			2012			2013			2012
Historical net loss per share:
Numerator:
Net loss attributed to common stockholders	$	(7,832	)	$	(5,935	)	$	(27,360	)	$	(18,945	)
Denominator:
Weighted-average common shares outstanding—denominator for basic and diluted net loss per share		32,634,683			24,375,749			28,664,822			20,738,007

Basic and diluted net loss per common share attributed to common stockholders	$	(0.24	)	$	(0.24	)	$	(0.95	)	$	(0.91	)

Computations of Diluted Weighted Average Shares Outstanding

The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding, as the effect of including such securities would be antidilutive:


	For the three months ended September 30,				For the nine months ended September 30,
	2013		2012		2013		2012
Warrants to purchase Common Stock		1,040,921		1,090,294		1,097,869		1,067,187
Options to purchase Common Stock		4,285,503		2,369,342		4,130,936		2,231,425

		5,326,424		3,459,636		5,228,805		3,298,612